The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Different predicted functional consequences of pharmacogenetics variants from the PharmGKB data. What's new?

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

The Open Targets Blog

MARCH 20, 2024

  We have implemented this analysis for eight sources of target-disease association evidence where there is enough information available to make an assessment. The assessment is tailored to each dataset; this is detailed in our target-disease evidence documentation. million evidence. DOI: 10.1016/j.ccell.2023.12.016

Pharmacogenetics 85

Pharmacogenetics Disease Drugs Research 85

ASPET

SEPTEMBER 16, 2024

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

The Open Targets Blog

NOVEMBER 30, 2023

Target prioritisation A major new feature of this release is the Target Prioritisation view, which provides an assessment of target-specific properties of interest when evaluating the suitability of a target for a drug discovery programme. Target prioritisation view for Crohn's Disease.

Pharmacogenetics 59

Pharmacogenetics Small Molecule Disease Drugs 59

ASPET

NOVEMBER 17, 2023

Quantitative pharmacokinetic models should therefore focus on OCT2/MATE when describing serum creatinine and creatinine clearance modulation by inhibitor drugs and genotype- or disease-related activity changes.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Disease Drugs 100

The Pharma Data

OCTOBER 27, 2020

Food and Drug Administration (FDA). SAN DIEGO , Oct. Clinical laboratories can process thousands of samples each day for less than $10 per sample running the assay on a single MassARRAY instrument, making it one of the highest throughput SARS-CoV-2 tests available under the Emergency Use Authorization program. SOURCE Agena Bioscience.

Pharmacogenetics 52

Pharmacogenetics Laboratories Clinical Research FDA 52